Orsiro Mission®DES

Arzneimitteleluierender Stent mit hervorragenden Patientenergebnissen

Finde mehr heraus Orsiro Mission®DES

Orsiro®DES

Orsiro DES, Verbesserung der Patientenergebnisse, Jahr für Jahr2

Finde mehr heraus Orsiro®DES

Clinical Studies

An extensive clinical program with more than 55,000 patients enrolled4

Find out more Clinical Studies

Test the next level of deliverability with Orsiro Mission

CONTACT US
Orsiro DES

Outstanding patient outcomes3​​​​​​​

Orsiro DES, improving patient outcomes, year after year*

BIOFLOW-V: 3-year results from the FDA pivotal trial

Find out more
News At a Glance

BIOTRONIK introduces next generation drug-eluting stent system in the CE region

READ ARTICLE

TCT 2018 – ultrathin Orsiro DES: wealth of clinical evidence for novel technology

READ ARTICLE

BIOTRONIK’s Orsiro DES continues to deliver excellent results after three years

READ ARTICLE
NewsRoom

*Compared to Xience, based on three consecutive years.
1. In comparison to Xience Sierra, Resolute Onyx and Synergy for bench tests on pushability, trackability and crossability, BIOTRONIK data on file; 2. As characterized with respect to strut thickness in Bangalore et al. Meta-analysis; 3. Based on investigator’s interpretation of BIOFLOW-V primary endpoint results; 4. BIOTRONIK data on file, status January 2020.

Orsiro and Orsiro Mission are trademarks or registered trademarks of the BIOTRONIK Group of Companies.

Disclaimer
Clinical data conducted with Orsiro, Orsiro Mission’s predecessor device can be used to illustrate Orsiro Mission clinical outcomes. 

Orsiro Mission is currently not available in the US.

© 2020 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.